- Home
- ANVS vs PMVP Comparison
ANVS vs PMVP Comparison
Compare ANVS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- PMVP
- Stock Information
- Founded
- ANVS 2008
- PMVP 2013
- Country
- ANVS United States
- PMVP United States
- Employees
- ANVS N/A
- PMVP N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- ANVS Health Care
- PMVP Health Care
- Exchange
- ANVS Nasdaq
- PMVP Nasdaq
- Market Cap
- ANVS 24.2M
- PMVP 71.9M
- IPO Year
- ANVS 2020
- PMVP 2020
- Fundamental
- Price
- ANVS $1.79
- PMVP $0.87
- Analyst Decision
- ANVS Strong Buy
- PMVP Strong Buy
- Analyst Count
- ANVS 5
- PMVP 2
- Target Price
- ANVS $34.75
- PMVP $5.50
- AVG Volume (30 Days)
- ANVS 525.3K
- PMVP 183.7K
- Earning Date
- ANVS 05-13-2025
- PMVP 05-09-2025
- Dividend Yield
- ANVS N/A
- PMVP N/A
- EPS Growth
- ANVS N/A
- PMVP N/A
- EPS
- ANVS N/A
- PMVP N/A
- Revenue
- ANVS N/A
- PMVP N/A
- Revenue This Year
- ANVS N/A
- PMVP N/A
- Revenue Next Year
- ANVS N/A
- PMVP N/A
- P/E Ratio
- ANVS N/A
- PMVP N/A
- Revenue Growth
- ANVS N/A
- PMVP N/A
- 52 Week Low
- ANVS $1.11
- PMVP $0.82
- 52 Week High
- ANVS $17.88
- PMVP $2.26
- Technical
- Relative Strength Index (RSI)
- ANVS 61.35
- PMVP 35.46
- Support Level
- ANVS $1.60
- PMVP $0.81
- Resistance Level
- ANVS $2.08
- PMVP $0.91
- Average True Range (ATR)
- ANVS 0.19
- PMVP 0.06
- MACD
- ANVS 0.04
- PMVP -0.00
- Stochastic Oscillator
- ANVS 59.72
- PMVP 24.30
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.